184 related articles for article (PubMed ID: 21196322)
1. MYCN, neuroblastoma and focal adhesion kinase (FAK).
Beierle EA
Front Biosci (Elite Ed); 2011 Jan; 3(2):421-33. PubMed ID: 21196322
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
[TBL] [Abstract][Full Text] [Related]
3. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.
Waters AM; Beierle EA
Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MYCN effector, FAK, in neuroblastoma.
Davidoff AM
Cell Cycle; 2010 Mar; 9(6):1026. PubMed ID: 20410685
[No Abstract] [Full Text] [Related]
5. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
Beierle EA; Ma X; Trujillo A; Kurenova EV; Cance WG; Golubovskaya VM
Mol Carcinog; 2010 Mar; 49(3):224-34. PubMed ID: 19885861
[TBL] [Abstract][Full Text] [Related]
7. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma.
Umapathy G; El Wakil A; Witek B; Chesler L; Danielson L; Deng X; Gray NS; Johansson M; Kvarnbrink S; Ruuth K; Schönherr C; Palmer RH; Hallberg B
Sci Signal; 2014 Oct; 7(349):ra102. PubMed ID: 25351247
[TBL] [Abstract][Full Text] [Related]
8. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
9. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
Calero R; Morchon E; Johnsen JI; Serrano R
PLoS One; 2014; 9(4):e95628. PubMed ID: 24759734
[TBL] [Abstract][Full Text] [Related]
11. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
13. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
[TBL] [Abstract][Full Text] [Related]
14. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
Megison ML; Stewart JE; Nabers HC; Gillory LA; Beierle EA
Clin Exp Metastasis; 2013 Jun; 30(5):555-68. PubMed ID: 23208732
[TBL] [Abstract][Full Text] [Related]
15. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
16. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
17. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
20. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
